A selective angiotensin receptor antagonist , Valsartan , produced <font color="blue">regression_2</font> <font color="blue">of_1</font> <font color="blue">left_1</font> <font color="blue">ventricular_1</font> <font color="blue">hypertrophy_1</font> associated with a <font color="blue">reduction_1</font> <font color="blue">of_1</font> <font color="blue">arterial_2</font> <font color="blue">stiffness_2</font> <font color="blue">._2</font> 
<br>
<br> We investigated whether a selective angiotensin II receptor blocker ( ARB ) would have a <font color="blue">regressive_2</font> <font color="blue">effect_2</font> <font color="blue">on_1</font> <font color="blue">left_1</font> <font color="blue">ventricular_1</font> <font color="blue">hypertrophy_1</font> <font color="blue">(_1</font> <font color="blue">LVH_1</font> <font color="blue">)_1</font> in patients on continuous ambulatory peritoneal dialysis ( CAPD ) . In a double - blind study , 24 CAPD patients with <font color="blue">LVH_1</font> <font color="blue">[_1</font> <font color="blue">left_1</font> <font color="blue">ventricular_1</font> <font color="blue">mass_1</font> <font color="blue">index_1</font> <font color="blue">(_1</font> <font color="blue">LVMi_1</font> <font color="blue">)_1</font> <font color="blue">>_1</font> <font color="blue">110_1</font> <font color="blue">g_1</font> <font color="blue">/_1</font> <font color="blue">m2_1</font> <font color="blue">for_1</font> <font color="blue">women_1</font> and <font color="blue">LVMi_1</font> <font color="blue">>_1</font> <font color="blue">137_1</font> <font color="blue">g_1</font> <font color="blue">/_1</font> <font color="blue">m2_1</font> <font color="blue">for_1</font> <font color="blue">men_1</font> <font color="blue">]_1</font> were randomized to 12 months ' administration of either the ARB valsartan ( n = 14 ) or a placebo ( n = 10 ) . The <font color="blue">target_1</font> <font color="blue">blood_2</font> <font color="blue">pressure_2</font> <font color="blue">(_2</font> <font color="blue">BP_2</font> <font color="blue">)_2</font> <font color="blue">was_1</font> <font color="blue">140/90_1</font> <font color="blue">mmHg_1</font> <font color="blue">or_1</font> <font color="blue">lower_1</font> in both groups . The following parameters were measured before and at the end of the study : <font color="blue">aortic_2</font> <font color="blue">and_2</font> <font color="blue">large_2</font> <font color="blue">-_2</font> <font color="blue">artery_2</font> <font color="blue">compliance_2</font> <font color="blue">and_1</font> <font color="blue">arterial_2</font> <font color="blue">wave_2</font> <font color="blue">reflections_2</font> <font color="blue">[_2</font> <font color="blue">pulse_2</font> <font color="blue">wave_2</font> <font color="blue">velocity_2</font> <font color="blue">(_2</font> <font color="blue">PWV_2</font> <font color="blue">)_2</font> <font color="blue">and_1</font> <font color="blue">augmentation_2</font> <font color="blue">index_2</font> <font color="blue">(_2</font> <font color="blue">AI_2</font> <font color="blue">)_2</font> <font color="blue">application_2</font> <font color="blue">tonometry_2</font> <font color="blue">]_2</font> <font color="blue">and_1</font> <font color="blue">cardiac_2</font> <font color="blue">echocardiography_2</font> <font color="blue">._2</font> Periodically recorded were <font color="blue">body_5</font> <font color="blue">weight_5</font> <font color="blue">,_5</font> <font color="blue">BP_5</font> <font color="blue">(_5</font> <font color="blue">mercury_5</font> <font color="blue">sphygmomanometer_5</font> <font color="blue">)_5</font> <font color="blue">,_5</font> <font color="blue">serum_5</font> <font color="blue">creatinine_5</font> <font color="blue">,_5</font> <font color="blue">electrolytes_5</font> <font color="blue">,_5</font> <font color="blue">complete_5</font> <font color="blue">blood_5</font> <font color="blue">cell_5</font> <font color="blue">counts_5</font> <font color="blue">,_5</font> <font color="blue">urine_5</font> <font color="blue">volume_5</font> <font color="blue">,_5</font> <font color="blue">drainage_5</font> <font color="blue">volume_5</font> <font color="blue">,_5</font> <font color="blue">and_4</font> <font color="blue">weekly_5</font> <font color="blue">creatinine_5</font> <font color="blue">clearance_5</font> <font color="blue">._5</font> Two - way analysis of <font color="blue">variance_1</font> <font color="blue">for_1</font> <font color="blue">repeated_1</font> <font color="blue">measurements_2</font> was used for statistical analysis . <font color="blue">Systolic_4</font> <font color="blue">and_4</font> <font color="blue">diastolic_4</font> <font color="blue">BP_4</font> were both <font color="blue">reduced_1</font> in patients treated with ARB . The <font color="blue">LVMi_4</font> <font color="blue">was_1</font> <font color="blue">significantly_1</font> <font color="blue">reduced_1</font> in patients treated with <font color="blue">ARB_1</font> <font color="blue">(_1</font> <font color="blue">to_1</font> <font color="blue">121_1</font> <font color="blue">+_1</font> <font color="blue">/-_1</font> <font color="blue">4_1</font> <font color="blue">from_1</font> <font color="blue">145_1</font> <font color="blue">+_1</font> <font color="blue">/-_1</font> <font color="blue">5_1</font> <font color="blue">)_1</font> but not in those receiving placebo ( to 137 + /- 3 from 152 + /- 3 , p < 0.05 ) . The decrease in <font color="blue">LVMi_3</font> was associated with a <font color="blue">reduction_1</font> <font color="blue">in_1</font> <font color="blue">PWV_2</font> <font color="blue">and_2</font> <font color="blue">AI_2</font> <font color="blue">._1</font> In CAPD patients with LVH , <font color="blue">ARB_1</font> <font color="blue">reduced_1</font> <font color="blue">LVMi_3</font> <font color="blue">in_1</font> <font color="blue">association_1</font> <font color="blue">with_1</font> <font color="blue">alterations_1</font> <font color="blue">in_1</font> <font color="blue">arterial_2</font> <font color="blue">hemodynamics_2</font> <font color="blue">._2</font>